PP
CDTX

Paloma Partners’s Cidara Therapeutics CDTX Stock Holding History

Paloma Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,350
Closed -$353K – 2115
2017
Q2 		$353K Buy
+2,350
New +$325K ﹤0.01% 1726

Other funds holding CDTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Paloma Partners's CDTX Position: Q3 2017 in Review

Paloma Partners sold out of Cidara Therapeutics (CDTX) in Q3 2017, closing a stake of 2,350 shares — an estimated $353K sold.

Paloma Partners first reported a position in CDTX in Q2 2017 and held it in 1 quarter. The position peaked at $353K in Q2 2017. 42 funds tracked by Wall St. Rank hold CDTX as of Q3 2017.

  • Paloma Partners reported no remaining Cidara Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Paloma Partners sold 2,350 Cidara Therapeutics shares in Q3 2017, an estimated $353K.
  • Paloma Partners first reported a position in Cidara Therapeutics in Q2 2017 and held it in 1 quarter.
  • Paloma Partners's Cidara Therapeutics position peaked at $353K in Q2 2017.
  • 42 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2017.

Based on Paloma Partners's 13F filing for Q3 2017, filed 14 Nov 2017.